Psychedelic Stock Gainers And Losers From October 6, 2022
GAINERS:
Revive Therapeutics (OTC:RVVTF) shares closed up 45.41% at $0.22
EXCLUSIVE: atai’s Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
Clinical-stage biopharma company atai Life Sciences N.V. (NASDAQ: ATAI) has commenced dosing volunteers for its ongoing Phase 1 clinical study investigating its proprietary DMT-based VLS-01 for treatment-resistant depression (TRD).
Cybin, GH Research Among Top Psychedelic Movers Of Today
GAINERS:
Cybin (AMEX:CYBN) shares closed up 20.50% at $0.58
Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin
Amended Autopsy Confirms Elijah McClain Died From Ketamine Injected By Paramedics Called By Cops
Allied, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS:
Mind Medicine (NASDAQ:MNMD) shares closed up 6.17% at $3.44
Psychedelic Stock Gainers And Losers From September 28, 2022
GAINERS:
Seelos Therapeutics (NASDAQ:SEEL) shares closed up 10.48% at $1.16
Biomind Labs, Allied Among Top Psychedelic Movers Of Today
GAINERS:
Biomind Labs (OTC:BMNDF) shares closed up 11.10% at $1.10
Psychedelic Stock Gainers And Losers From September 21, 2022
GAINERS:
Revive Therapeutics (OTC:RVVTF) shares closed up 7.87% at $0.32
Seelos Therapeutics, Allied Among Top Psychedelic Movers Of Today
GAINERS:
Allied (OTC:ALID) shares closed up 7.83% at $0.62
Great Psychedelics And Business Events Are Coming In Q4: Check Them Out Here
The season for psychedelics conferences is right around the corner. From very large and well-known events to small meets, this year’s remaining months are loaded with on-site and virtual discussions around the natural plant and synthetic medicines revolutionizing mental health.